Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors.

Journal for immunotherapy of cancer - 1 Jan 2021

Hao Xingxing, Falo Iii Louis D, Chen Guo, Zhang Jiying, Carey Cara D, Storkus Walter J, Falo Louis D, You Zhaoyang

Abstract excerpt

BACKGROUND: Despite the remarkable benefits associated with the interventional treatment of melanomas (and other solid cancers) with immune checkpoint and Braf inhibitors (Brafi), most patients ultimately progress on therapy. The presence of multifocal/disseminated disease in patients increases their mortality risk. Hence, the development of novel strategies to effectively treat patients with melanomas that are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Synergism
Share to Immune Checkpoint Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunization

Share to Intramolecular Oxidoreductases

Share to PTEN Phosphohydrolase

Share to Tamoxifen

Share to Vaccines, DNA

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 33408093
DOI: 10.1136/jitc-2020-001179
PMCID: PMC7789470

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors.PMID 33408093Read ↗

Comprehensive immune profiling of melanoma-draining lymph nodes identifies plasmacytoid dendritic cells as new biomarker for PD-L1 blockadeSemantic proximity Read ↗

Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T cell receptor signallingSemantic proximity Read ↗

Changes in the TCRβ Repertoire and Tumor Immune Signature From a Cutaneous Melanoma Patient Immunized With the CSF-470 Vaccine: A Case Report.Semantic proximity Read ↗

Multi-model preclinical platform predicts clinical response of melanoma to immunotherapySemantic proximity Read ↗

Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.Semantic proximity Read ↗

Identification of highly cross-reactive mimotopes for a public T cell response in murine melanomaSemantic proximity Read ↗

Exploiting the Mutanome for Tumor VaccinationSemantic proximity Read ↗

Evaluation of genetic melanoma vaccines in cdk4-mutant mice provides evidence for immunological tolerance against authochthonous melanomas in the skin.Semantic proximity Read ↗

Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity.Semantic proximity Read ↗

Systemic effects of melanoma-secreted MIDKINE in the inhibition of dendritic cell differentiation and functionSemantic proximity Read ↗

T cell immunotherapy for melanoma from bedside to bench to barn and back: how conceptual advances in experimental mouse models can be translated into clinical benefit for patients.Semantic proximity Read ↗

Caerin 1.1 and 1.9 peptides halt B16 melanoma metastatic tumours via expanding cDC1 and reprogramming tumour macrophagesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.